Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other equities analysts also recently weighed in on ARTV. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. HC Wainwright lifted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $11.27 on Friday. The company’s 50 day simple moving average is $9.36 and its 200-day simple moving average is $7.74. The firm has a market capitalization of $278.56 million, a PE ratio of -3.42 and a beta of 2.16. Artiva Biotherapeutics has a 12 month low of $2.22 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). As a group, sell-side analysts anticipate that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32. Following the completion of the acquisition, the director directly owned 15,203,995 shares of the company’s stock, valued at $175,150,022.40. This trade represents a 74.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Corp. Gc acquired 1,085,069 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $11.52 per share, with a total value of $12,499,994.88. Following the transaction, the insider owned 4,391,969 shares of the company’s stock, valued at approximately $50,595,482.88. This trade represents a 32.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders acquired 9,907,958 shares of company stock valued at $107,688,019 and sold 53,040 shares valued at $477,890. Insiders own 21.40% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $79,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth approximately $58,000. Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $67,000. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics during the second quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.